Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.93
-0.04 (-0.24%)
At close: Jul 17, 2026, 4:00 PM EDT
16.96
+0.03 (0.18%)
After-hours: Jul 17, 2026, 4:10 PM EDT
Theravance Biopharma Employees
Theravance Biopharma had 90 employees as of December 31, 2025. The number of employees decreased by 7 or -7.22% compared to the previous year.
Employees
90
Change (1Y)
-7
Growth (1Y)
-7.22%
Revenue / Employee
$1,219,722
Profits / Employee
$1,272,678
Market Cap
877.45M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 90 | -7 | -7.22% | 90 | 0 |
| Dec 31, 2024 | 97 | -2 | -2.02% | 97 | 0 |
| Dec 31, 2023 | 99 | -12 | -10.81% | 99 | 0 |
| Dec 31, 2022 | 111 | -48 | -30.19% | 111 | 0 |
| Dec 31, 2021 | 159 | -200 | -55.71% | 158 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pharming Group | 407 |
| Phathom Pharmaceuticals | 371 |
| Geron | 258 |
| DBV Technologies | 161 |
| Solid Biosciences | 121 |
| Odyssey Therapeutics | 100 |
| Vor Biopharma | 76 |
| Design Therapeutics | 54 |
TBPH News
- 10 days ago - Theravance Biopharma downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 17 days ago - Zymeworks price target raised to $37 from $35 at Citi - TheFly
- 18 days ago - Theravance Biopharma downgraded to Neutral from Buy at BTIG - TheFly
- 18 days ago - Theravance Biopharma downgraded to Hold from Buy at JonesResearch - TheFly
- 18 days ago - Theravance Biopharma Proxy statement: Proxy filing - Filings
- 18 days ago - Why This Biotech Stock Is Falling After a $929 Million Buyout Lifeline - Barrons
- 18 days ago - M&A News: Biotech Group Zymeworks Buys Lung Disease-Fighting Peer Theravance for $1B - TipRanks
- 18 days ago - Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash - TheFly